Novartis to make commercial Carvykti; Recipharm divests seven facilities; Lilly’s Zepbound in shortage 

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential updates on new builds, collaborations, recalls and more.

Novartis extended its deal with Johnson & Johnson and Legend Biotech to commercially manufacture Carvykti, according to a March 29 SEC filing. Novartis will make the CAR-T…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks